Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JJP 1008

Next Previous
X
Search
Drug Profile

JJP 1008

Alternative Names: anti-CD270 therapeutic antibody - JJP Biologics; anti-HVEM therapeutic antibody - JJP Biologics; JJP-1008

Latest Information Update: 19 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JJP Biologics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; Tumour necrosis factor ligand superfamily member 14 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 19 Mar 2024 Preclinical trials in Solid tumours in Poland (Parenteral), before March 2024 (JJP Biologics communication, March 2024)
  • 03 Nov 2022 JJP 1008 is available for licensing as of 03 Nov 2022. https://jjpbiologics.com/pipeline/
  • 03 Nov 2022 Early research in Solid tumours in Poland (Parenteral) (JJP Biologics website, November 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top